Wolfe Research initiated coverage of GRAIL with a rating of Peer Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/27/2024 | $16.00 | Equal-Weight | Morgan Stanley |
| 11/15/2024 | Peer Perform | Wolfe Research | |
| 10/17/2024 | Neutral | Guggenheim |
MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern
Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees
4 - GRAIL, Inc. (0001699031) (Issuer)
4 - GRAIL, Inc. (0001699031) (Issuer)
4 - GRAIL, Inc. (0001699031) (Issuer)
SC 13G - GRAIL, Inc. (0001699031) (Subject)
SC 13G - GRAIL, Inc. (0001699031) (Subject)
SC 13G/A - GRAIL, Inc. (0001699031) (Subject)
Morgan Stanley initiated coverage of GRAIL with a rating of Equal-Weight and set a new price target of $16.00
Wolfe Research initiated coverage of GRAIL with a rating of Peer Perform
Guggenheim initiated coverage of GRAIL with a rating of Neutral
Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif., Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business
MENLO PARK, Calif., Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter 2024 following the close of market on Thursday, Feb. 20, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. Fourth Quarter 2024 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the in
Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Into 2028 MENLO PARK, Calif., Nov. 12, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter 2024. Revenue in the third quarter was $28.7 million, representing 38% growth year over year, and revenue for Galleri was $25.4 million, representing 52% growth year over year. Ne
Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif., Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business
USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 19, 2025 /PRNewswire/ -- USA News Group News Commentary – Amid the excitement surrounding Project Stargate—the $500 billion investment aimed at revolutionizing AI-driven data centers—concerns over the rising global cancer rates, particularly among younger populations, remain pressing. Lifestyle factors are increasingly under scrutiny, with the World Health Organization (WHO) now advocating for cancer warning labels on alcohol products. Despite these alarming trends, several biotech companies have already made notable strides in 2025, with recent advancements coming from Oncolytics Biotech Inc. (NASD
MENLO PARK, Calif., Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter 2024 following the close of market on Thursday, Feb. 20, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. Fourth Quarter 2024 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the in
8-K - GRAIL, Inc. (0001699031) (Filer)
8-K - GRAIL, Inc. (0001699031) (Filer)
10-Q - GRAIL, Inc. (0001699031) (Filer)